4- [3- (4-cyclopropanecarbonyl-piperazine-I-carbonyl) -4 -fluoro-benzyl] -2H-phthalaz in-1-one
4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline Form L, methods of obtaining form L, pharmaceutical compositions comprising Form L and methods of using Form L and compositions comprising Form L.
1. 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline Form L.
2. The compound of claim 1 having the following characteristic peaks in a powder XRD:
2θ° (±0.1°)
Peak
(λ = 1.5418 Å)
1
14.4
2
17.2
3
17.5
4
18.8
5
23.0.
3. The compound of claim 1 having the following characteristic peaks in a powder XRD:
2θ° (±0.1°)
Peak
(λ = 1.5418 Å)
1
14.4
2
17.2
3
17.5
4
18.8
5
23.0
6
10.4
7
13.6
8
25.1.
4. The compound of claim 1 , which has an onset of melting at 198.5° C.±1° C. when heated from 25° C. to 325° C. at 10° C. per minute in DSC.
5. A method of obtaining 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline Form L from 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline Form A, comprising slurrying 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as either Form A or a mixture of Forms A and L in an organic solvent selected from the group consisting of methanol, ethanol, acetone, acetonitrile and nitromethane; that optionally contains up to 30% water v/v.
6. A pharmaceutical composition comprising a compound having crystalline Form L according to claim 1 and a pharmaceutically acceptable carrier or diluent.
7. A compound having crystalline Form L according to claim 1 for use in a method of treatment of the human or animal body.
8. A compound having crystalline Form L according to claim 1 for the use in a method of inhibiting PARP in the treatment of the human or animal body.